Pregabalin Capsule
Product Images NDC 70518-2763

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 70518-2763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Packaging label for Pregabalin 200 mg capsules by RemedyRepack Inc. The label indicates a quantity of 90 capsules, controlled substance schedule C-V, Rx only. Manufacturer is Novadoz Pharmaceuticals LLC, New Jersey. Contains storage instructions and a QR code.*

FDA Label Image

Equation (Pregabain Gault Equation)

This image displays a formula for calculating creatinine clearance (CLCr), involving age, weight, serum creatinine levels, and an adjustment factor for female patients. It is a text panel with a mathematical equation relevant to clinical assessments.*

FDA Label Image

Fig-01 (Pregabalin Figure 01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline with Pregabalin doses of 200 mg, 100 mg, and 25 mg three times a day compared to placebo. The graph shows higher patient improvement percentages with increasing Pregabalin dosage.*

FDA Label Image

Fig-02 (Pregabalin Figure 02)

A line graph comparing percent improvement in pain from baseline between Pregabalin 100 mg three times a day and placebo. The y-axis shows percent of patients improved, and the x-axis shows percent improvement in pain. The graph displays two lines: a dashed line for pregabalin and a dotted line for placebo, illustrating higher improvement percentages for pregabalin across pain improvement thresholds.*

FDA Label Image

Fig-03 (Pregabalin Figure 03)

A Kaplan-Meier plot showing the percent of patients improved versus percent improvement in pain from baseline, comparing four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo. The y-axis represents percent of patients improved; the x-axis depicts percent improvement in pain from baseline. Different line styles distinguish each treatment group.*

FDA Label Image

Fig-04 (Pregabalin Figure 04)

A Kaplan-Meier plot showing the percent of patients improved on the vertical axis versus percent improvement in pain from baseline on the horizontal axis. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, each represented by different line styles. The plot depicts patient response rates at various levels of pain improvement.*

FDA Label Image

Fig-05 (Pregabalin Figure 05)

A line graph depicting the percent of patients improved relative to percent improvement in pain from baseline for Pregabalin (100 mg and 50 mg three times a day) and placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis represents percent of patients improved (0 to 100%). Three lines show patient response across different pain improvement levels for each treatment group.*

FDA Label Image

Fig-06 (Pregabalin Figure 06)

A bar chart comparing responder rates (%) from two studies, Study E1 and Study E3. Study E1 shows responder rates for placebo and Pregabalin administered at doses of 50 mg, 150 mg, 300 mg, and 600 mg per day (BID). Study E3 shows responder rates for placebo and Pregabalin at 600 mg per day given BID and TID. Each bar is labeled with the percentage responder rate and the sample size (N) is noted below the x-axis for each treatment group.*

FDA Label Image

Fig-07 (Pregabalin Figure 07)

A line graph depicting seizure reduction as median percent change from baseline against Pregabalin doses in mg/day (0, 50, 150, 300, 600). Four groups are represented by different markers: Stukly E1BID (solid circles), E2BID (open squares), E3BID (solid triangles), and E3TID (open triangles). P-values indicating significant differences are annotated near data points.*

FDA Label Image

Fig-09 (Pregabalin Figure 09)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 600 mg, 450 mg, and 300 mg daily doses compared to placebo. The graph includes four curves representing each dose and placebo, with data points plotted from 0 to 100 percent improvement.*

FDA Label Image

Fig-10 (Pregabalin Figure 10)

A Kaplan-Meier survival curve comparing the estimated percentage of subjects without LTR over a 180-day period between Pregabalin and placebo groups. The y-axis represents the estimated percentage of subjects without LTR, ranging from 0% to 100%, and the x-axis shows time in days from 0 to 180. Two lines depict the data: a solid line for Pregabalin and a dashed line for placebo, illustrating different survival rates over time.*

FDA Label Image

Fig-11 (Pregabalin Figure 11)

A line graph comparing the percent of subjects improved over a range of improvement percentages from baseline to week 12 using last observation carried forward (BOCF). It features two lines: a solid line representing Pregabalin and a dotted line representing Placebo, charting the percent of subjects improved against varying thresholds of percent improvement.*

FDA Label Image

Fig-12 (Pregabalin Figure 12)

A line graph showing the percent of subjects improved versus percent improved from baseline to week 16 using BOCF method. The graph compares Pregabalin (solid line) to Placebo (dashed line), illustrating a higher percentage of subjects improved with Pregabalin over the Placebo across the improvement spectrum from 0 to 100 percent.*

FDA Label Image

Str (Pregabalin Structure)

Chemical structure diagram of Pregabalin, showing its molecular arrangement with amino, methyl, and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.